AION Biosystems named quarterfinalist in 2026 Digital Health & AI Awards

AION Biosystems has been named a Quarterfinalist in the 2026 Digital Health & AI Awards for its TempShield continuous temperature monitoring system. The recognition highlights growing interest in tools that detect infection earlier in high-risk patients across home, hybrid and remote care.

Why it matters: - TempShield aims to turn body temperature into an earlier warning signal for infection, which could give care teams more time to intervene. - The category focuses on home, hybrid and remote care, where missed changes between checks can leave high-risk patients exposed. - The recognition places AION Biosystems among technologies shaping digital health and AI in care settings beyond the hospital.

What happened: - AION Biosystems said Oct. 2 that it was named a Quarterfinalist in the 2026 Digital Health & AI Awards. - The company was recognized in the Home, Hybrid & Remote Care – Rising Star category. - The Digital Health & AI Awards evaluate companies and innovations across digital health, AI and healthcare technology. - Quarterfinalists advance to the next stage of judging, with Finalists announced Oct. 12, 2026. - The competition ends Nov. 16 at HLTH in Las Vegas, where winners will be announced live.

The details: - AION Biosystems makes TempShield continuous temperature monitoring, or CTM. - TempShield monitors body temperature continuously for up to 90 days. - The system takes 288 readings a day. - TempShield alerts care teams to early shifts that can signal infection before symptoms appear. - AION says the technology is designed to provide earlier warning for high-risk patients wherever they receive care. - Samara Barend, CEO of AION Biosystems, said temperature is one of the earliest signals of decline and that the award recognizes the gap in care between visits or checks. - Mark H. Goldstein, chairman of the Digital Health Hub Foundation, said the awards spotlight technologies and leaders moving healthcare forward.

Between the lines: - The award underscores a push to move infection detection earlier, before symptoms force a clinical response. - Continuous monitoring may matter most in settings where patients are not under constant observation. - AION is positioning temperature as a biomarker, similar to how glucose monitoring changed diabetes care. - The company also ties the product to goals of reducing hospitalization and mortality.

What's next: - AION Biosystems will move through the next round of judging. - Finalists will be announced Oct. 12, 2026. - The company’s standing could gain more visibility ahead of the HLTH finale in Las Vegas. - AION continues to promote TempShield as a wearable patch plus clinical intelligence platform for infection detection.

The bottom line: - AION Biosystems is getting recognition for a monitoring tool it believes can spot infection earlier, especially in care settings where missed changes can carry the highest risk.